UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 17, 2015

TherapeuticsMD, Inc.

(Exact Name of Registrant as Specified in its Charter)

Nevada

(State or Other Jurisdiction of Incorporation) 001-00100

(Commission File Number)

87-0233535

(IRS Employer Identification No.)

6800 Broken Sound Parkway NW, Third Floor Boca Raton, FL 33487

(Address of Principal Executive Office) (Zip Code)

Registrant's telephone number, including area code: (561) 961-1900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2 below):

£ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

£ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

£ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

£ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

TherapeuticsMD, Inc. is furnishing as Exhibit 99.1 to this Current Report on Form 8-K an investor presentation which will be used, in whole or in part, and subject to modification, on August 17, 2015 and at subsequent meetings with investors or analysts.

The information in this Current Report on Form 8-K (including the exhibit) is being furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor will any of such information or exhibits be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d)

Exhibits.	
Exhibit <u>Number</u>	Description
99.1	TherapeuticsMD, Inc. presentation dated August 2015.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 17, 2015

THERAPEUTICSMD, INC.

By: /s/ Daniel A. Cartwright


Name: Daniel A. Cartwright Title: Chief Financial Officer

EXHIBIT INDEX

Exhibit
NumberDescription99.1TherapeuticsMD, Inc. presentation dated August 2015.

Exhibit 99.1





www.TherapeuticsMD.com

THER-0061 V3 8/15

Forward-Looking Statements

This presentation by TherapeuticsMD, Inc. (referred to as "we" and "our") may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as "believe," "hope," "may," "anticipate," "should," "intend," "plan," "will," "expect," "estimate," "project," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of our managerial experience and perception of historical trends, current conditions, expected future developments and other factors we believe to be appropriate.

Forward-looking statements in this presentation are made as of the date of this presentation, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which may be outside of our control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well our current reports on Form 8-K, and include the following: our ability to maintain or increase sales of our products; our ability to develop, protect and defend our intellectual property; our ability to develop and commercialize our hormone therapy drug candidates and obtain additional financing necessary therefor; the length, cost and uncertain results of our clinical trials; potential adverse side effects or other safety risks that could preclude the approval of our hormone therapy drug candidates; our reliance on third parties to conduct our clinical trials, research and development and manufacturing; the availability of reimbursement from government authorities and health insurance companies for our products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of our common stock; and the concentration of power in our stock ownership.

PDF copies of press releases and financial tables can be viewed and downloaded at our website: http://www.therapeuticsmd.com/pressreleases.aspx.

Therapeutics MD[®]


TherapeuticsMD (TXMD)

Innovative women's health company exclusively focused on developing and commercializing products for women throughout their life cycles




Drug candidate portfolio is built on patented SYMBODA[™] technology, developed to enable new bio-identical hormone combinations, forms and administration routes

Pipeline Targets Large Markets




Key Milestones



TX-004HR VVA Program

Overview – Vulvar and Vaginal Atrophy (VVA)

- Diagnosed in approximately 50% of postmenopausal women¹
- Most bothersome symptom commonly reported is dyspareunia¹
- FDA guidance for efficacy requirements:
 - Statistically significant increase in superficial cells
 - Statistically significant decrease in parabasal cells
 - Statistically significant change in vaginal pH
 - Statistically significant reduction in severity of dyspareunia



VVA Market – Established and Growing

- U.S. sales more than doubled since 2008
- Global market expected to be \$2.1 billion in 2022^₄
- · Currently no generic competition
- 32 million U.S. women currently experiencing VVA symptoms


Product ²	Compound	TRx ¹ 12 Month Rolling (000)	U.S. Sales (\$MM) ¹ 12 Month Rolling	WAC Price ³
Premarin® Cream	Equine vaginal estrogen	1,774	\$511	\$263.52
Vagifem® Tablets	Vaginal estradiol	1,851	\$463	\$306.00*
Estrace® Cream	Vaginal estradiol	1,751	\$406	\$240.05
Osphena® Tablets	Oral SERM	280	\$67	\$158.00
Estring [®]	Vaginal estradiol ring	336	\$99	\$283.66
Total		5,992	\$1,546	

.

Ferning data is excluded due to VMS indication. Medi-Span Price Rx Basic as of 61(V15). * for 18 tablets (\$136.00 WAC for 8 tablets) (BobalData JV) 2013 report GHC54PDR.


All trademarks are the property of their respectiv

VVA Market Dynamics – Ready for New Product




4) Portman, D, et al. One Year Treatment Pensistence with Local Estrogen Therapy in Postmenopausal Women Diagnosed as Having Vaginal Alrophy Menopause: The Journal of The North American Menopause Society Vol. 22, No. 11, Published online ahead of print May 4, 2015.

30MM Women with VVA Untreated in U.S.**



Vagifem[®] 25 mcg to 10 mcg Market Share

TX-004HR – Target Product Profile



TX-004HR Vaginal Estradiol U.S. Launch Timeline



· ·								
Q1 '15	Q2 '15	Q3 '15	Q4 '15	Q1 '16	Q2 '16	Q3 '16	Q4 '16	Q1 '17
		Enrollment Completed	Topline Report					
				N	DA Prep/Fi	iling/PDUFA	•	
	Pha	ise 3						
	II ¹ : 12 weel	ks, ~100 sit	tes of June 20					


- 175 placebo
- FDA required Co-Primary Endpoints for Proposed Indication

(from baseline to week 12 versus placebo)^{2,3}

- Statistically significant increase in the % of vaginal superficial cells
- Statistically significant decrease in the % of vaginal parabasal cells
- Statistically significant change in vaginal pH
- Statistically significant reduction in the severity of dyspareunia
- Additional Endpoints
- PK measures Days 1,14, 84
- FSFI (Female Sexual Function Index), acceptability survey
 - Therapeutics MD*
- 2) Each arm (4 mag, 10 mag, and 25 mag) tested against each co-primary endpoint.
 3) The FDA has noted that a single, large, well-controlled clinical that to support safety and efficacy should be sufficient to submit an NDA for TX-004HR for the indicate and that the summary the indicate is a clinic of different for a cline different for a should be sufficient to submit an NDA for TX-004HR for the indicate of different for a should be sufficient to submit an NDA for TX-004HR for the indicate of different for a should be sufficient to submit an NDA for TX-004HR for the indicate of different for a should be sufficient to submit an NDA for TX-004HR for the indicate of different for a should be sufficient to submit an NDA for TX-004HR for the indicate of different for a should be sufficient to submit an NDA for TX-004HR for the indicate of different for a should be sufficient to submit an NDA for TX-004HR for the indicate of different for a should be sufficient to submit an NDA for TX-004HR for the indicate of different for a should be sufficient to submit an NDA for TX-004HR for the indicate of different for a should be different for a should be sufficient to submit an NDA for TX-004HR for the indicate of different for a should be different

TX-004HR Phase 3 Trial Timelines & Milestones





TX-004HR Phase 2 Study Double-blind and Placebo-controlled

Study Design

- 48 postmenopausal women with VVA (24 active, 24 placebo)
- Randomized 1:1 to 10 mcg; 1x daily for 2-week period
- Endpoints measured at 2 weeks; same endpoints to be measured in Phase 3 at 12 weeks

Co-primary Endpoint Results¹

- Increase in superficial cells 35% treatment vs. 4% placebo (P=0.0002)
- Decrease in parabasal cells 54% treatment vs. 4% placebo (P<0.0001)
- Decrease in vaginal pH -0.97 units for treatment vs. -0.34 units for placebo (P=0.0002)
- · Numerical reduction of most bothersome symptoms

Secondary Endpoint Results


- Improved patient satisfaction, 97% said easy to use²
- Reduction in atrophic effects on epithelial integrity and vaginal secretions^a

Heckar, J.H. et al., Plot and Pharmacoknetic Studies of Solublized Estination Amministered Vaginaly in a Softgel Cappule. Menopause. 2014. Vol 23, No. 12, S.B., 1328.
 Kingsberg, Sheryl "Patient Experience with Solublized Estination Given Vaginaly in a Novel Softgel Cappule. (Vag/CapTM) preserved 2015 Annual Meeting ISSWSH, Peb 20, 2015.
 Constantine, G.D., "Vaginal Physical Examination Correlates with Vaginal Epithelial Cells and pH and Can Be Used to Assess Therapeutic Efficacy," FRI-126.

TX-004HR vs. Vagifem[®] Phase 1 Single Dose PK Studies

Key Findings

- Tmax ~2 hours with TX-004HR and ~8 hours with Vagifem
- Systemic absorption AUC (0-24 hours) is 2- to 3-fold lower with TX-004HR relative to Vagifem



Therapeutics MD*

16

Vagifem is a registered trademark of Novo Nordisk A/S Corp.

TX-001HR Combination Program

Menopause Overview

Menopause represents the natural life-stage transition when women stop having periods and may result in physical and emotional symptoms.

- Average age of menopause is 51 years¹
- Hot flashes are due to lower estrogen levels
- Estrogen is given to reduce hot flashes
- Estrogen causes the uterus to thicken (hyperplasia)
- Progesterone is given to non-hysterectomized women to prevent thickening of the uterus

FDA Approved Hormone Therapy Market Size

FDA-Approved Product		U.S. Sales (\$MM) ¹	Company
17β Estradiol + NETA / DSP Activella [®] / FemHRT [®] / Angeliq [®]	Non bio-identical containing progestins	\$37	WARNER DAVER NOVO nordisk
Generic 17β + Progestins	Non bio-identical containing progestins	\$230	Pharmaceuticals
Premarin + MPA Prempro [®] / Premphase [®]	Non bio-identical CEE + progestin	\$339	Pfizer
Premarin + SERM Duavee®	Non bio-identical CEE + SERM	\$19	Pfizer
Paroxetine Brisdelle®	SSRI non-hormonal	\$36	
Total FDA-Approved Oral Co	ombination Sales	\$661	

10

1) Symphony Health Salutions PHAST 2.0 Prescription Monthly Data, 12 months as of June 30, 2016. All trademarks are the property of their respective owners.

Hormone Therapy Market = Two Markets

Total Combination E+P Market

\$2.2 billion =


\$661MM¹ FDA-Approved No Bio-identical Combinations

\$1,500MM²


Compounded Bio-identical Estradiol / Progesterone

Symphony Health Solutions PHAST 2.0 Prescription Monthly Data, 12 months as of June 30, 2015.
 Pinkerton, J.V. 2015. Menopause, Vol.22, No.9, pp 0-11.

Number of U.S. Women Using Non-FDA-Approved Compounded HT



Evidence Supports Bio-identical Progesterone Favorable Clinical Profile Compared to Synthetic Progestins



Evidence Supports Bio-identical Estradiol Favorable Clinical Profile Compared to Conjugated Estrogens

"CEEs (Premarin) were associated with a higher incidence of venous thrombosis and myocardial infarction than estradiol."

- Journal of the American Medical Association, September 2013

"Oral estradiol may be associated with a lower risk of stroke ... compared with conventional-dose oral CEE."²

- Menopause, September 2014

The ELITE trial demonstrated that estradiol is cardioprotective when given during the early postmenopausal years.³ — *Circulation*. November 2014

Cochrane meta analysis demonstrated that estradiol is cardioprotective and reduced overall mortality when given 10 years before the onset of menopause.⁴

- Cochrane Collaboration, 2015

Therapeutics MD*

2) Shufet et al. Hormone Therapy Dose, Formulation, Route of Delivery, and Risk of Cardiovascular Events in Women: Findings from the Women's Health Initiative Observational Study. 3) Abstract 13283: Testing the Menopausal Hormone Therapy Timing Hypothesis: The Early versus Late Intervention Trial with Estradol (HN Hodis, et al.1 Circulation, 2014; 130:A13283.

Medical Societies Express Concern Over Compounded Hormones











- ACOG and ASRM Committee Opinion states compounded hormones may pose additional risks compared to FDA approved products¹
 - Lack of Good Manufacturing Practices (GMP)
 - · Variable purity
 - Variable content uniformity
 - Variable potency (under/over dose)
 - Not approved for efficacy and safety
 - Lack of stability data
- Medical societies' global consensus statement declares that the use of custom-compounded hormone therapy is not recommended²

 Committee on Gynecologic Practice and the American Society for Reproductive Medicine Practice Committee, Number 532, August 2012 (Reaffirmed 2014, Replaces No. 387, November 2007 and No. 322, November 2006).
 Villers, T.J. et al., Global Consensus Statement on Menopausal Hormone Therapy, Climaclovic, June 2013, Vol. 16, No. 3: Pages 316-337.

Compounding Regulations and Enforcement

Drug Quality and Security Act (DQSA)

 Prohibits compounding of essential copies of an FDA-approved drug except in limited circumstances such as drug shortages

inSecurityAct/upm376829.htm

 Anticipate significant impact on compounding upon FDA-approval of first combination hormone therapy product

USP 800 – Hazardous Drugs²³


- New identification requirements for receipt, storage, mixing, preparing, compounding, dispensing, and administration of hazardous drugs
- Considered "prohibitively expensive" requiring major pharmacy upgrades and renovations to be compliant

7808.pc





TX-001HR – Target Product Profile



TX-001HR Estradiol + Progesterone U.S. Launch Timeline

 Q1 '15
 Q2 '15
 Q3 '15
 Q4 '15
 Q1 '16
 Q2 '16
 Q3 '16
 Q4 '16
 Q1 '17
 Q2 '17
 Q3 '17
 Q4 '17
 Q1 '18

 Phase 3 Vasomotor & Endometrial Safety

 NDA Prep/Filing/ PDUFA

- Phase 3 Replenish Trial to enroll 1,750 subjects at ~100 U.S. sites
 - Four active arms (N=400/arm)
 - Estradiol 1 mg/Progesterone 100 mg
 - Estradiol 0.5 mg/Progesterone 100 mg
 - Estradiol 0.5 mg/Progesterone 50 mg
 - Estradiol 0.25 mg/Progesterone 50 mg

https://clinicatrials.gov/ct2/show/NCT019426687term=replenish+trial&rank=1

Placebo arm (N=150)

٠

- Keplenish
- 12-month study with 12-week VMS substudy endpoints:
 - · Vasomotor substudy: number and severity of hot flashes (4 weeks and 12 weeks)
 - Endometrial safety: incidence of endometrial hyperplasia (12 months)


Early Stage Pipeline: Transdermal Programs

Why Transdermal?


- Transdermal delivery perceived safer due to a lower first-pass effect
- No FDA-approved transdermal progesterone
- New TXMD PK data suggest leveraging solubilized progesterone, show elevated and sustained transdermal levels
- Leveraging this technology creates an opportunity for new progesterone IP, products and novel dosage forms

E+P Topical PK Results

New Formulation PK Data Suggest Sustained 8-hour Duration¹



Proof Of Concept Efficacy Study¹



Transdermal Market Opportunity

Product (Combination E+P)	TRx ¹ (000)	U.S. Sales (\$MM) ¹	Company
Estradiol/Levonorgestrel (Climara Pro®)	111	\$23	BAUER
Estradiol/Norethindrone Acet (CombiPatch [®])	383	\$58	
Total Combination Transdermal Sales	494	\$81	
Product (Estradiol Only)	TRx ¹ (000)	U.S. Sales (\$MM) ¹	Company
Estradiol (Patch, Gel, Spray) (Alora [®] , Climara [®] , Estraderm [®] , Menostar [®] , Vivelle [®] , Vivelle-Dot [®] , Minivelle [®] ; Divigel [®] , Elestrin [®] , Estrogel [®] ; Evamist [®])	5,674	\$814	UNOVARTIS Allergan
Total Estradiol Transdermal Sales	5,674	\$814	
Symphony Health Solutions PHAST 2.0 Prescription Month All trademarks are property of their respective owners.	ly Data, 12 months as of June	• 30, 2015.	TherapeuticsM

Intellectual Property Update

Growing Patent Portfolio

	Filed	Provisional	Non- Provisional	Issued	
U.S.	48	15	22	11	
Ex-U.S.	61				

- Seven new patents issued in 2015 strengthening competitive barriers to entry and building on layered coverage strategies
- · Others issued:
 - Field spanning estradiol and progesterone pharmaceutical compositions and methods
 - · OPERA reporting and analysis software patent
- Layered patent strategies
 - Field spanning pharmaceutical compositions and methods by family of estradiol and progesterone alone and in combination
 - Siloed strategy for each product


Worldwide Patent Filings*

Strong IP Portfolio with 61 Patents Pending in 12 Jurisdictions Outside the United States



"Not all patent filings filed in all jurisdictions.

35



Investment Rationale

- Worldwide commercial rights for multiple hormone therapy products in Phase 3 and earlier stages:
 - Well-known chemical entities with established safety and efficacy thresholds; 505(b)(2)
 - Unique, large, and growing markets with favorable competitive dynamics (DQSA)
 - Additional early stage pipeline candidates
 - Strong foreign IP portfolio with 61 patent applications pending in 12 foreign jurisdictions
- Growing U.S. commercial business marketing prescription and OTC prenatal vitamins
 - Customer base of OB/GYNs and other women's health specialists
 - Recognized by Deloitte Technology Fast 500 as 41st in North America
- Experienced management team with proven development and commercial success in women's health

TXMD: Financial Snapshot




Thank You!

TherapeuticsMD[®]

www.TherapeuticsMD.com



Long-Term Growth Opportunity



TX-004HR Phase 2 Study Patient Experience Secondary Endpoint

Patient Experience Survey Results Summary

- 97% reported "easy to use"
- 96% reported the TX-004HR softgel (VagiCap^{**}) was "easy to insert"
- 94% reported "convenient to use"
- 0% experienced expulsion of capsule
- >60% "very satisfied"; 8% were "dissatisfied"
- 63% reported quality of life was "somewhat better" to "much better" after only 14 days of use



1) Kingsberg, Sheryl. 'Pati ISSWSH, Feb 20, 2015. Neeting Ir